Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.0%

Neg 0% Neu 89% Pos 0%

Guggenheim analyst Paul Jeng reiterates Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $5 price target.

Comments

No comments yet. Be the first!